RE:RE:RE:Let me state the obvious Regarding the 18 month continuation comment.
they were referring to on- going operating & continued inplace trial costs.
They do have funding & support for the Pancreatic cancer " enabling trial" through the CGAR support.
That trial, will be simplified as they do not need a control group. Being allowed to use existing inplace data.
That opportunity cuts the enrolment needs in half & thus the cost.
bring a very fatal disease, once certain conditions are met, then can ask for accelerated approval.
People greatly need to appreciate. Onc is not running the trials.
CGAR is , alongside Roche very qualified advisors.
Many want this to sucseed.
regarding the MBc trials. They do not have funding & 100% need outside funding.
Being a licensing deal or complete buyout.
My opinion , FWIW , I see a buyout from Roche.
when?
Roche people are listed as co- authors & advisors of the just announced abstracts.
Now time for the techical people ( PhDs ) to talk with the finance people.
lawyers, accountants, advisors etc etc.
Assuming the 32 million share day last week was an ATM fill.
gives Onc stronger negotiating power.